Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard High Dividend Yield ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B), while Vanguard High Dividend Yield ETF trades at $158.24 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 47.1× Recursion Pharmaceuticals Inc's market cap, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| RXRX | VYM | |
|---|---|---|
Market Cap | $2.14B | $100.80B |
Volume | 30,789,535 | 908,176 |
Sector | Health | — |
52-Week High | $6.79 | $167.03 |
52-Week Low | $2.84 | $137.47 |
Typical Hold Time | 22 Days | 138 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
VYM trades at $157.45, down 0.58% with a bearish technical signal. The ETF shows neutral oscillators but bearish moving averages, with support at $157 and resistance at $158. Recent news highlights VYM's consistent dividend yield of 2.42% but notes performance lag versus peers like SCHD and IDV, which have outperformed year-to-date.
VYM faces competition from higher-yielding alternatives and exhibits vulnerability to dividend cuts in its holdings. The ETF's broad diversification provides stability, but investors may seek better returns elsewhere. Key risks include sector concentration and interest rate sensitivity affecting dividend appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
